491 related articles for article (PubMed ID: 27727015)
1. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.
Harris VK; Vyshkina T; Sadiq SA
Cytotherapy; 2016 Dec; 18(12):1476-1482. PubMed ID: 27727015
[TBL] [Abstract][Full Text] [Related]
2. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis.
Harris VK; Stark J; Vyshkina T; Blackshear L; Joo G; Stefanova V; Sara G; Sadiq SA
EBioMedicine; 2018 Mar; 29():23-30. PubMed ID: 29449193
[TBL] [Abstract][Full Text] [Related]
3. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis.
Harris VK; Yan QJ; Vyshkina T; Sahabi S; Liu X; Sadiq SA
J Neurol Sci; 2012 Feb; 313(1-2):167-77. PubMed ID: 21962795
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cell-derived neural progenitors in progressive MS: Two-year follow-up of a phase I study.
Harris VK; Stark JW; Yang S; Zanker S; Tuddenham J; Sadiq SA
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33277427
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial.
Harris VK; Stark J; Williams A; Roche M; Malin M; Kumar A; Carlson AL; Kizilbash C; Wollowitz J; Andy C; Gerber LM; Sadiq SA
Stem Cell Res Ther; 2024 May; 15(1):151. PubMed ID: 38783390
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study.
Yamout B; Hourani R; Salti H; Barada W; El-Hajj T; Al-Kutoubi A; Herlopian A; Baz EK; Mahfouz R; Khalil-Hamdan R; Kreidieh NM; El-Sabban M; Bazarbachi A
J Neuroimmunol; 2010 Oct; 227(1-2):185-9. PubMed ID: 20728948
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.
Petrou P; Kassis I; Levin N; Paul F; Backner Y; Benoliel T; Oertel FC; Scheel M; Hallimi M; Yaghmour N; Hur TB; Ginzberg A; Levy Y; Abramsky O; Karussis D
Brain; 2020 Dec; 143(12):3574-3588. PubMed ID: 33253391
[TBL] [Abstract][Full Text] [Related]
8. Autologous mesenchymal stromal cell transplantation for spinal cord injury: A Phase I pilot study.
Satti HS; Waheed A; Ahmed P; Ahmed K; Akram Z; Aziz T; Satti TM; Shahbaz N; Khan MA; Malik SA
Cytotherapy; 2016 Apr; 18(4):518-22. PubMed ID: 26971680
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
[TBL] [Abstract][Full Text] [Related]
10. Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis.
Harris VK; Faroqui R; Vyshkina T; Sadiq SA
Stem Cells Transl Med; 2012 Jul; 1(7):536-47. PubMed ID: 23197858
[TBL] [Abstract][Full Text] [Related]
11. Intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chronic lower back pain: a long-term safety and feasibility study.
Elabd C; Centeno CJ; Schultz JR; Lutz G; Ichim T; Silva FJ
J Transl Med; 2016 Sep; 14(1):253. PubMed ID: 27585696
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy.
Dahbour S; Jamali F; Alhattab D; Al-Radaideh A; Ababneh O; Al-Ryalat N; Al-Bdour M; Hourani B; Msallam M; Rasheed M; Huneiti A; Bahou Y; Tarawneh E; Awidi A
CNS Neurosci Ther; 2017 Nov; 23(11):866-874. PubMed ID: 28961381
[TBL] [Abstract][Full Text] [Related]
13. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
Cohen JA; Imrey PB; Planchon SM; Bermel RA; Fisher E; Fox RJ; Bar-Or A; Sharp SL; Skaramagas TT; Jagodnik P; Karafa M; Morrison S; Reese Koc J; Gerson SL; Lazarus HM
Mult Scler; 2018 Apr; 24(4):501-511. PubMed ID: 28381130
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Use of Intrathecal Mesenchymal Stem Cells in patients with Multiple Sclerosis: A Pilot Study with Booster Injection.
Sahraian MA; Mohyeddin Bonab M; Baghbanian SM; Owji M; Naser Moghadasi A
Immunol Invest; 2019 Feb; 48(2):160-168. PubMed ID: 30156938
[TBL] [Abstract][Full Text] [Related]
15. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
[TBL] [Abstract][Full Text] [Related]
16. Bone Marrow-Derived Mesenchymal Stem Cells as Autologous Therapy in Dogs with Naturally Occurring Intervertebral Disc Disease: Feasibility, Safety, and Preliminary Results.
Steffen F; Smolders LA; Roentgen AM; Bertolo A; Stoyanov J
Tissue Eng Part C Methods; 2017 Nov; 23(11):643-651. PubMed ID: 28471303
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS;
Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636
[TBL] [Abstract][Full Text] [Related]
18. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.
Uccelli A; Laroni A; Brundin L; Clanet M; Fernandez O; Nabavi SM; Muraro PA; Oliveri RS; Radue EW; Sellner J; Soelberg Sorensen P; Sormani MP; Wuerfel JT; Battaglia MA; Freedman MS;
Trials; 2019 May; 20(1):263. PubMed ID: 31072380
[TBL] [Abstract][Full Text] [Related]
19. Multiple Autologous Bone Marrow-Derived CD271
Milczarek O; Jarocha D; Starowicz-Filip A; Kwiatkowski S; Badyra B; Majka M
Stem Cells Transl Med; 2018 Jan; 7(1):20-33. PubMed ID: 29224250
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal injection of CD133-positive enriched bone marrow progenitor cells in children with cerebral palsy: feasibility and safety.
Zali A; Arab L; Ashrafi F; Mardpour S; Niknejhadi M; Hedayati-Asl AA; Halimi-Asl A; Ommi D; Hosseini SE; Baharvand H; Aghdami N
Cytotherapy; 2015 Feb; 17(2):232-41. PubMed ID: 25593079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
